Optimum’s clients sunny perspective as summer approaches

From a major international investment event, to a new way to use the complement system to fight cancer, here’s what Optimum and its clients have been doing this week. 

Novo Nordisk Foundation, Wellcome, and the Bill & Melinda Gates Foundation join forces to accelerate global health equity and Novo Nordisk Foundation gives grants for global science projects 

On Monday, the Novo Nordisk Foundation, Wellcome, and the Bill & Melinda Gates Foundation announced a new partnership to support critical scientific research and development for global health. The partnership is focused on supporting science and innovation to advance solutions that are accessible and affordable to people in low- and middle-income countries. 

The joint partnership will support science to tackle a series of global health challenges and build healthier futures, especially for the world’s most vulnerable populations. 

On Tuesday, the Novo Nordisk Foundation followed this with an international open call for research projects to catalyse science-based solutions to key global challenges. The programme expects to hand out up to eight grants each worth up to $1 million, with a total awarding budget of up to DKK 50 million (USD 7.1 million). 

Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib 

Calliditas Therapeutics AB on Monday announced data from the proof-of-concept Phase 2 trial evaluating setanaxib, its lead NOX enzyme inhibitor, in combination with pembrolizumab, in patients with squamous cell carcinoma of the head and neck (SCCHN).  The analysis showed statistically significant improvements in progression-free survival (PFS), as well as in overall survival (OS), with statistically significant changes in tumour biology consistent with the mechanism of action of setanaxib. 

Commit Biologics launches with €16m seed financing to pioneer complement system activation to treat cancer and autoimmune disease 

Commit Biologics, a pioneer in the activation of the complement system to treat cancer and autoimmune disease, on Thursday exited from stealth with €16m in seed funding from Bioqube Ventures and Novo Holdings. 

Unlike many complement focused therapies which seek to inhibit complement, Aarhus, Denmark-based Commit is pioneering a novel approach to activating the complement component of the immune system to kill targeted cells and treat cancer and autoimmune diseases. 

Optimum’s clients head for sunny San Sebastian and Bio€quity Europe 

Optimum’s clients will take a starring role at this weekend’s Bio€quity Europe 2024, held in San Sebastian, Spain from Sunday until Tuesday. A major international investment event, the conference brings together leading companies in the sector and specialist investors looking for new opportunities and projects. 

Clients attending are Adcendo, Ariceum, Asceneuron, the BioInnovation Institute, Calliditas, Curve Therapeutics, Commit Biologics, Disco Pharmaceuticals, Engimmune Therapeutics, Fibrocor Therapeutics, iOnctura, Kling Biotherapeutics, medicxi, Minervax, Mission Therapeutics, Novo Holdings, Ona Therapeutics, Outrun Therapeutics, Oxolife, Rejuvenate Biomed, Sofinnova Partners, SpliceBio, Storm Therapeutics, Synendos Therapeutics, SynOx, Vesper Bio, Vivet Therapeutics, and Women in Life Science Denmark (WiLD). Get in touch with us if you would like to arrange a meeting.